within Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CA02_Ergotamine;

model Ergotamine
  extends Pharmacolibrary.Drugs.ATC.N.N02CA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N02CA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ergotamine is an ergot alkaloid used for the acute treatment of migraine attacks and cluster headaches. It is a vasoconstrictor and acts by stimulating alpha-adrenergic and serotonergic (5-HT1) receptors. Use of ergotamine has declined due to the availability of triptans and its side effect profile. It is currently approved in some countries but less commonly used.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both sexes, following a single oral dose.</p><h4>References</h4><ol><li><p>Perrin, VL (1985). Clinical pharmacokinetics of ergotamine in migraine and cluster headache. <i>Clinical pharmacokinetics</i> 10(4) 334–352. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198510040-00004&quot;>10.2165/00003088-198510040-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3899452/&quot;>https://pubmed.ncbi.nlm.nih.gov/3899452</a></p></li><li><p>Sanders, SW, et al., &amp; Jaeger, H (1986). Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. <i>European journal of clinical pharmacology</i> 30(3) 331–334. DOI:<a href=&quot;https://doi.org/10.1007/BF00541538&quot;>10.1007/BF00541538</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3732370/&quot;>https://pubmed.ncbi.nlm.nih.gov/3732370</a></p></li><li><p>Diener, HC (2005). Eletriptan in migraine. <i>Expert review of neurotherapeutics</i> 5(1) 43–53. DOI:<a href=&quot;https://doi.org/10.1586/14737175.5.1.43&quot;>10.1586/14737175.5.1.43</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15853473/&quot;>https://pubmed.ncbi.nlm.nih.gov/15853473</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ergotamine;
